TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published in the Journal of Clinical Investigation reports brain changes in people with pulmonary hypertension, including tissue loss and weaker communication between regions involved in memory, attention and planning. The researchers linked these changes to inflammation involving the NCOA7 gene, but the findings do not yet establish a screening test or treatment.
Researchers at the University of Pittsburgh and UPMC report that pulmonary hypertension is associated with distinct brain changes linked to inflammation, offering a possible biological explanation for patients’ memory and concentration problems. The study, published November 2 in the Journal of Clinical Investigation, also implicates the NCOA7 gene, but it does not establish a clinical screening test or treatment.
The team compared brain MRI scans from people with pulmonary hypertension with scans from people without the condition. They used information from a large public health database and a separate, smaller group of UPMC patients to test and confirm the findings. In both groups with pulmonary hypertension, researchers reported substantial brain-tissue loss and weaker communication between the cerebellum and frontal lobe, regions involved in memory, attention and planning.
The researchers said these differences were not found in comparison groups with other heart, lung or psychiatric conditions. They also reported that the changes could not be explained by low blood oxygen, impaired heart function or medications used to treat pulmonary hypertension. Those results support an association specific to the disease in the groups studied; they do not, by themselves, show that every patient will experience cognitive symptoms.
Genetic analyses and laboratory work connected the brain findings with a variant in NCOA7, a gene previously linked by the team to inflammatory responses in pulmonary hypertension. Examination of cerebellum tissue from patients and mice showed signs of overactive microglia, the brain’s immune cells, as well as changes in neurons. In mice with pulmonary hypertension, removing the gene was associated with more severe cerebellar damage, which the researchers said supports a role for NCOA7 in regulating brain inflammation.
Why Brain Changes Matter in Pulmonary Hypertension
Pulmonary hypertension raises blood pressure in the vessels carrying blood through the lungs and is commonly associated with shortness of breath, chest pain and lightheadedness. The study adds potential brain involvement to the picture, suggesting that memory or executive-function difficulties reported by patients may relate to the disease process rather than being separate concerns.
That distinction could matter for clinical conversations and future research. The researchers say current pulmonary hypertension management guidelines do not include cognitive screening, and there is no established biological marker to predict or track the condition’s effects on the brain. The study points toward a possible marker and inflammation as a research target, but neither is ready to be treated as a validated clinical tool.
The work may also prompt investigation of whether related inflammatory mechanisms occur in other conditions. That possibility remains a hypothesis: the study focused on pulmonary hypertension, and it does not show that NCOA7 causes cognitive decline or dementia across other diseases.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Theragun Relief Special Edition Bundle
Fitbit Inspire 3 Health and Fitness Tracker Bundle
As an affiliate, we earn on qualifying purchases.
From Lung Inflammation to Brain Findings
The study builds on earlier work by Stephen Chan and colleagues identifying an NCOA7 variant associated with inflammatory responses in pulmonary hypertension. According to the report, the variant is present in about one-quarter of pulmonary hypertension patients and is associated with worse survival odds. Chan hypothesized that the same biology could be relevant to inflammation in the brain.
To examine that possibility, the researchers combined brain imaging and blood-test data with genetic analysis and laboratory studies. They assessed findings in a public health dataset and a separate UPMC patient group, then examined tissue from patients and mice. The paper is titled Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis and appeared in the Journal of Clinical Investigation on November 2, 2026 (DOI: 10.1172/jci195110).
“This changes the way we look at a disease like pulmonary hypertension. In medicine, we typically treat the symptoms of one organ system; but the reality is that our bodies are very complex, and disease processes may be affecting multiple parts of the body in a variety of ways.”
— Stephen Chan, M.D., Ph.D., University of Pittsburgh and UPMC
Limits of the Cognitive Findings
The report does not provide enough detail here to establish how often cognitive impairment occurs across all people with pulmonary hypertension, how the brain changes relate to symptom severity, or whether they progress over time. The imaging comparisons and laboratory findings support a link, but they do not establish that the observed changes directly cause memory or attention problems in each patient.
The proposed biological marker has not been described as a validated screening or monitoring test, and the study does not report a treatment that prevents or reverses the changes. The suggested relevance to other inflammatory conditions is also unconfirmed. Further work would be needed to assess the findings in broader patient groups and determine their usefulness in clinical care.
Testing Markers and Clinical Screening
The study’s findings set up further research into whether NCOA7-related inflammation can reliably identify people at risk of brain changes and whether those changes track with cognitive symptoms over time. Researchers would also need to test any proposed marker in additional groups before it could guide screening or treatment decisions.
For now, the report does not announce a change to pulmonary hypertension guidelines. Chan’s team argues that cognitive symptoms deserve attention, while the potential for screening and therapies targeting inflammation remains a subject for further study. The researchers’ next clinical steps and timeline were not specified in the source report.
Key Questions
What did the study find?
Researchers reported brain-tissue loss and weaker communication between the cerebellum and frontal lobe in the pulmonary hypertension groups they examined. They also found evidence linking these changes to inflammation involving NCOA7.
Does pulmonary hypertension cause memory problems?
The study offers a possible biological explanation for cognitive symptoms reported by some patients, but the findings do not prove that the brain changes directly cause symptoms in every person with pulmonary hypertension.
Is there a test to screen for these brain changes?
Not based on this report. The researchers identified a potential biological marker, but it has not been established as a clinical screening or monitoring test.
Does the study identify a treatment?
No. It points to inflammation as a possible research target, but does not report a treatment shown to prevent or reverse the brain changes.
Could the findings apply to dementia or aging?
Chan suggested that NCOA7-related inflammation may be relevant to other conditions, including those linked to dementia and aging. That is a research hypothesis, not a result established by this pulmonary hypertension study.
Source: news-medical.net
